EM2510E "Pneumocystis jirovecii Pneumonia" (IM GR-102425)

Purpose and Overview

PJP remains a serious complication of immundeficient states and HIV infection. Although the use of highly active anti-retroviral therapies has lessened the impact of PJP in patients with HIV the constant development of new immune modulating therapies for hematologic malignancies, autoimmune diseases, and transplant patients has lead to the emergence of PJP in these populations. As opposed to HIV, significant differences in terms of clinical presentation and rationale for prophylaxis exist. Delayed recognition of PJP is associated with significantly worse outcome. Recent data on diagnostic pathways, treatment efficay, the role of glucocorticosteroids, and the use of prophylactic therapy will be reviewed.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  •  To understand changes in the epidemiology of PJP
  • To understand newer approaches to diagnosis of PJP involving PCR and fungitell
  •  Utilize current data on treatment and prophylaxis of PJP
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
10/30/2025
Course expires: 
12/31/2025
Cost:
$0.00
Rating: 
0

Photo: First Last, M.D.
Jonathan Weissler, M.D.
Professor of Internal Medicine
Division of Pulmonary & Critical Care Medicine

Available Credit

  • 1.00 AMA

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome